CA Patent

CA2917839C — Piperidinyl indole derivatives and their use as complement factor b inhibitors

Assigned to Novartis AG · Expires 2022-05-03 · 4y expired

What this patent protects

The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitors of the complement alternative pathway, in particular of Factor B. The present invention further provides a combination of …

USPTO Abstract

The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitors of the complement alternative pathway, in particular of Factor B. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

Patent Metadata

Patent number: CA2917839C
Jurisdiction: CA
Classification: —
Expires: 2022-05-03
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.